Navigation Links
GlycoMark Blood Test Included in Global Diabetes Care Guidelines as Emerging Technology
Date:9/25/2007

AMSTERDAM, Netherlands, Sept. 25 /PRNewswire/ -- At the 2007 annual meeting of the European Association for the Study of Diabetes (EASD), the International Diabetes Federation (IDF) issued the new global diabetes guidelines of diabetes care which includes the management of postmeal glucose. These guidelines include the GlycoMark blood test as a new emerging technology to measure postmeal glucose.

In a released statement, the IDF indicated that the guideline emphasizes that people with diabetes should have their blood glucose levels closely monitored after meals in order to optimize diabetes control and reduce the risk of complications, particularly cardiovascular disease. This new approach to managing postmeal glucose will assist clinicians and organizations in developing effective strategies for managing diabetes.

"Diabetes is now recognized as one of the largest epidemics humanity has ever faced and a leading cause of death. It accounts for 3.8 million deaths per year, many of which are related to cardiovascular disease. This new advancement underscores the importance for people with diabetes and their healthcare providers to adopt all possible ways to better manage the disease," said Professor Stephen Colagiuri, Chair of the IDF Task Force on Clinical Guidelines.

The new IDF Guideline recommends that people with diabetes try to keep postmeal blood glucose levels to less than 7.8 mmol/l (140 mg/dl) two hours following a meal. IDF advises SMBG (self-monitoring of blood glucose) because it is the most practical method for measuring postmeal glucose and it allows people with diabetes to obtain "real-time" information about their glucose levels. This information enables people with diabetes and their healthcare providers to make timely adjustments in their treatment regimens to achieve and maintain their blood glucose levels within target. The guideline also includes the 1,5-anhydroglucitol blood test (GlycoMark) and continuous glucose monitor
'/>"/>

SOURCE BioMarker Group
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Recommendations for Treatment of Blood Pressue
2. Blood Cells Capable of Regenerating Liver
3. Infant receives first bloodless liver transplant
4. Spouses and other partners lower blood pressure says new research
5. H2O - a cure for low blood pressure
6. Uncontrolled blood pressure
7. Weight and Blood Pressure
8. Grandmother’s diet in pregnancy can affect grandchildren’s blood sugr
9. Early diagnosis for autism from blood tests may be possible
10. Antibiotic from crab blood indentified
11. Gum disease may be caused by blood clotting gene
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...tiretroviral therapy may be due to genetic factors... A new study challenges the long-held belief that ...tem,s ability to restore itself after HIV patients...rapy (HAART). , From 50 percent to 90 percent o...CV. Intravenous drug use is the main cause of both...
(Date:7/25/2008)...ng overweight or obese is not only a personal issu...ealth issue that impacts other people in society. ...ch reveals that the extra Medicare cost associate...nificant financial burden on tax payers, costing u...tire current Medicare population. , The article...
(Date:7/25/2008)... consumers tips and encourages them to, ,Speak Up...., July 25 /PRNewswire-USNewswire/ -- The Pennsylv...onal Patient Safety Day" which,is a national effor...icipate fully in their healthcare by asking questi...urgery or illness., "We understand the important ...
(Date:7/25/2008)...the number of jobs created in the medical field sl...different kind of slowdown: they laid off fewer pe... Seattle, WA (PRWEB) July 25, 2008 -... field slowed in June overall, pharmaceutical comp...ill be music to the ears of sales representatives:...
Breaking Medicine News(10 mins):Health News:Study Disproves Belief That Hepatitis C Blunts HIV Drugs 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 3Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3
...ted by the type 3 virus which spreads by bugs and ...t most of the winegrowers have bought the national...free from the virus. New Zealand Winegrowers scien...said that a lot of research is being done to under...
... Journal of the National Cancer Institute, childho...premature menopause//. Ovarian irradiation and ce...ost common risk factors associated with early meno...hildren or adolescents diagnosed with cancer will ...
...MA) has issued a warning that the nation could be ... future due to a lack of clinical expertise. Dr M...the federal MPs and senators insisting for a strat... deal with the increase in number of students. He ...
...that inhabitants of Phet where hundreds of poultry...since they had a feast on these birds. Public hea...ichit are trying to create awareness of bird flu a...usly here. Dr. Prachak Wattanakun, a provincial he...
Other Medicine News:
(Date:7/23/2008)...ing publication in July print edition of Clinical ... INDIANAPOLIS, July 23 /- A Roche Dia...of N-terminal pro-B-type natriuretic peptide,(NT-p...or risk,stratification in predicting the risk of c...reated with non-steroidal anti-inflammatory drugs ...
(Date:7/23/2008)...y 23 /- InCode BioPharmaceutics, Inc....ounced preclinical test,results demonstrating the ... treatment of the rare chronic blood disorder paro...e results will be presented at the XXII,Internatio...tember 28,2008., The only treatment currently av...
(Date:7/22/2008)...22 /- Nonin Medical, a leading innova... than 20 years, has entered,the clinical testing p...egional oxygen saturation. Today,s most common app...itoring of the regional blood oxygenation,in the b...d outcomes from an ongoing clinical study at the,D...
(Date:7/22/2008)...ing Lantus(R) and Apidra(R) Resulted in Significan...tes, Whatever the Algorithm ...wswire/ -- Results from the "Adjust to,Target in T...o Carbohydrate,Counting for Adjustment of Mealtime...merican Diabetes Association,s (ADA) medical journ...
Breaking Medicine Technology:Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 3Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 4InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) 2Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments 19147 1TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments 19147 2TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments 19147 3TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments 19147 4TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments 19147 5TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments 19147 6TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments 19147 7Psychology com Seeing Growing Acceptance of Online Therapy 19145 1Psychology com Seeing Growing Acceptance of Online Therapy 19145 2Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results 5337 1Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results 5337 2Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results 5337 3Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results 5337 4Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results 5337 5Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results 5337 6Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results 5337 7NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide Donating Agent in Hypertensive Patients by Merck 26 Co Inc 2046 1NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide Donating Agent in Hypertensive Patients by Merck 26 Co Inc 2046 2NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide Donating Agent in Hypertensive Patients by Merck 26 Co Inc 2046 3
...VERLY, Mass.--(BUSINESS WIRE)--Mar 27, 2007 - Inot... presentation of,positive Phase 2 clinical data de...potential for INO-1001 as a preventative agent for...ed in subjects,with acute ST-elevated myocardial i...coronary intervention. The presentation was,made i...
...ETHESDA, Md., March 27, 2007--A new study shows th...e proportion of,cardiovascular disease (CVD) linke... emphasize the need for increased efforts to,preve...CVD risk,factors among those with diabetes, accord...amingham Heart Study, a program of the,National He...
Other Medicine Technology:Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 2Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 3Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical,Data for INO-1001 at ACC Demonstrating PARP Inhibition and,Anti-inflammatory Activity in Plasma of Patients Undergoing Primary,Percutaneous Coronary Intervention 4Increasing Proportion of Cardiovascular Disease Due to Diabetes,Over the Last 50 Years 2Increasing Proportion of Cardiovascular Disease Due to Diabetes,Over the Last 50 Years 3
No Scalpel Vasectomy Ring Clamp, 5 1/2" (14cm), gold finger rings
Non-Cantilevered, "Teardrop" Ringed Forceps. ("fixation clamp") For vasectomy and other procedures. Ring ovoid approximately 6.0 mm in diameter.
Li Brand™ Ringed Forceps. ("fixation clamp") For NSV and other procedures. Ring diameter approximately 3.5 mm. Manufactured exclusively for AMI to exacting specifications by a German company.
...dule is an inconspicuous, lightweight, battery-ope...need to hear body functions amplified., ,The modu... integrated on/off switch, a tone switch, a stetho... The tone switch will allow the user to select bet...
Medicine Products: